Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

iShares U.S. Pharmaceutical ETF (NY:IHE)

64.62 -0.08 (-0.12%)
Streaming Delayed Price Updated: 11:12 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares U.S. Pharmaceutical ETF

< Previous 1 2 Next >
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
Via Benzinga
Topics ETFs Government
Exposures Political
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Exposures Political
3 Sector ETFs That Beat The Market Last Week
Here are three ETFs from different sectors that were in green last week. 
Via Talk Markets
Topics ETFs
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On?
Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain. 
Via Benzinga
Topics World Trade
Exposures Tariff
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors. 
Via Benzinga
Topics ETFs Government World Trade
Exposures Political Tariff
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally. 
Via Benzinga
US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget
A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21. 
Via Benzinga
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely. 
Via Benzinga
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase. 
Via Benzinga
Topics ETFs
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency. 
Via Benzinga
Topics Government
Exposures Political Product Safety
Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.
Robert Kennedy Jr. revealed Trump's directive to tackle health agency corruption, promote science, and end chronic disease. 
Via Benzinga
Topics Government
Exposures Political
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest... 
Via Talk Markets
Topics ETFs
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market
Performance in April 2024: Utilities lead, real estate lags. S&P 500, Nasdaq 100, Dow Jones Industrial Average, small-cap and large-cap indices all decline. 
Via Benzinga
Topics Stocks
Exposures US Equities
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
Bank Of America Predicts 10 2024 Market Surprises: From Booming IPOs To Japanese Equity Surge
Bank of America lists 10 market surprises; warns investors to be wary of the bond market's dovish position compared to the Fed. 
Via Benzinga
Topics Bonds
Exposures Debt Markets
3 Beaten-Down ETFs To Buy For A Turnaround In 2024
Following three consecutive monthly losses since the COVID pandemic began in March 2020, Wall Street recorded a robust recovery starting in November. we have highlighted ETFs from different zones that... 
Via Talk Markets
Topics ETFs
Exposures COVID-19
5 Secret Santa ETFs That Might Surprise You This Christmas
Wall Street has been sizzling hot this holiday season. This is likely to continue, given that the Santa Claus rally is on the way. Against such a backdrop, there are some hidden gems which could... 
Via Talk Markets
Topics ETFs
Pharmacy Workers Strike At CVS and Walgreens, Echoing Wider Pharma Sector Unrest
In a recent surge of labor unrest, pharmacy employees from CVS Health Corporation (NYSE: CVS) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) raised their voices by calling out sick or walking out... 
Via Benzinga
5 Sector ETFs That Outperformed in Turbulent August
Wall Street has lost momentum since the start of August, triggered by the series of bank downgrades and fears of higher rates for a longer-than-expected period. 
Via Talk Markets
Topics ETFs
Q2 Earnings & Market Sell-Off Impact: 5 Must-See ETF Charts
While longer-than-expected rate worries and banking concerns led to feeble trading in recent weeks, a few equity ETFs rose or saw a modest decline over the past month. 
Via Talk Markets
Topics ETFs
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
3 Biotech Stocks to Sell in June Before They Crash and Burn
Investors should get out of these biotech stocks to sell now that the Covid-19 pandemic is largely over. These's worse in store for them. 
Via InvestorPlace
Pharma ETFs Gain Post Q1 Earnings
Pharma ETFs have been in the green over the past month. 
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.